The market’s gaining steam – and so is your opportunity to lock in serious income. Our ‘Easy Income Portfolio’ has been ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

MarioGuti Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks ...

Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

India has launched a new digital platform, Ayush Nivesh Saarthi, in a move aimed at mainstreaming India’s traditional ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform ...